Athira Pharma Net Tangible Assets Over Time
| ATHA Stock | USD 0.64 0.02 3.03% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Athira Pharma Performance and Athira Pharma Correlation. Athira |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.48) | Return On Equity (0.85) |
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Athira Pharma and related stocks such as CytomX Therapeutics, Spero Therapeutics, and Neoleukin Therapeutics Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTMX | (81.2 M) | (81.2 M) | (81.2 M) | (81.2 M) | (81.2 M) | 123.4 M | 75.8 M | 67.3 M | 128.5 M | 48.9 M | 47.7 M | 87.4 M | (2.4 M) | (2.8 M) | (2.7 M) |
| SPRO | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (37.5 M) | 84.6 M | 115.5 M | 74.6 M | 132 M | 88.3 M | 75.9 M | 87.3 M | 70.9 M |
| TIL | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (55.4 M) | 555.2 M | 555.2 M | 638.5 M | 670.4 M |
| NXTC | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (46.9 M) | 321.5 M | 293.7 M | 233.4 M | 167.5 M | 192.7 M | 173.2 M |
| ASMB | 34.5 M | 34.5 M | 17.8 M | 24.5 M | 16.8 M | 77.1 M | 38.2 M | 113.1 M | 169 M | 231.6 M | 198.9 M | 168.9 M | 82.7 M | 95.1 M | 107.5 M |
| ACHL | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 12.7 M | 101.3 M | 189.2 M | 289.5 M | 197 M | 226.6 M | 173.7 M |
| NUVB | (744 K) | (744 K) | (744 K) | (744 K) | (744 K) | (744 K) | (744 K) | (744 K) | (744 K) | (24.1 M) | (52.4 M) | 746 M | 655.1 M | 753.3 M | 791 M |
Athira Pharma and related stocks such as CytomX Therapeutics, Spero Therapeutics, and Neoleukin Therapeutics Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Athira Pharma | ATHA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Washington; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.64
Check out Athira Pharma Performance and Athira Pharma Correlation. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Athira Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.